Outsourcing in Clinical Trials New England 20147-8 October 2014, Boston, MA
Welcome to the flagship event in our global Outsourcing in Clinical Trials Series. Last year over 400 pharmaceutical, biotechnology and medical device professionals attended Outsourcing in Clinical Trials New England event to learn from case-study based presentations, network with their peers, discover new solutions and services and find answers to all of their clinical challenges.
With such enthusiasm around this conference, this October’s event will once again bring together the industry leaders from within this hub for two days of presentations, case studies, panel discussions and roundtables, alongside the networking opportunity. With over 50 speakers participating, the content will cover all aspects of clinical outsourcing from informed sourcing and efficient contract negotiation through to effective management, monitoring and communication techniques.
Whether you are a senior professional in a global pharmaceutical company or a smaller company looking to expand, access to insight and knowledge about the latest pharmaceutical trends is vital.
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news. The list of websites will be updated as soon as new events are live so check back regularly
We are always happy to see photos taken at our events! If you have any you would like to submit, please email firstname.lastname@example.org The Arena Team
Primary delegates for this event are those with responsibility for clinical outsourcing decisions and strategy within biotechnology, pharmaceutical, virtual and medical device companies throughout Southern California.
Outsourcing in Clinical Trials New England boasts a fantastic exhibition of clinical service providers and industry specialists. Our exhibition area is already filling up due to the fantastic launch event which took place this year. If you have a service or solution you would like to promote at this event, please use the details below to make contact with our commercial team.
Swiss drug maker Roche has reported positive data from the coBRIM Phase III trial of the combination of cobimetinib and Zelboraf (vemurafenib) to treat patients with BRAF V600 mutation-positive advanced melanoma.
Novartis has reported final results from a Phase III trial of Afinitor (everolimus) tablets plus best supportive care (BSC) compared to placebo plus BSC in patients with well-differentiated advanced and progressive pancreatic neuroendocrine tumours (…
US-based biopharmaceutical firm Akebia Therapeutics has dosed the first patient in its Phase II clinical trial of AKB-6548 in patients with anaemia related to chronic kidney disease (CKD) undergoing dialysis.
Canadian biopharmaceutical firm Helix BioPharma has initiated patient enrolment for the tenth dose level group in its ongoing Phase I/II clinical trial (LDOS002) of L-DOS47 in Poland to treat certain patients with non-small cell lung cancer (NSCLC).
Swiss drug-maker Novartis has reported positive results from two of its pivotal Phase III trials (FUTURE 1 and FUTURE 2) of an investigational medicine secukinumab (AIN457) in patients with psoriatic arthritis (PsA).
US-based biopharmaceutical firm Zafgen has completed patient enrolment in its Phase IIa clinical trial (ZAF-221) of Beloranib to treat hypothalamic injury-associated obesity (HIAO).